Diagnosis of ectopic adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH) co-secreting tumors causing Cushing syndrome (CS) is challenging because these tumors are rare and their diagnosis is frequently confused with Cushing disease (CD), caused by the effect of CRH on the pituitary. We report a case of a 21-year-old male patient who was referred to our institution with persistent hypercortisolemia and CS after undergoing unnecessary transsphenoidal surgery (TSS). 68 Ga-DOTA-TATE PET/CT revealed increased tracer uptake in the thymus, which was histologically proven to be a neuroendocrine tumor (NET) that stained positive for ACTH and CRH. Imaging with 18 F-FDG PET/CT was not diagnostic.
. A 21-year-old male patient presented with sudden onset of rapid weight gain, central adiposity, facial plethora, fatigue, loss of muscle mass, insomnia, anxiety, and decreased libido. The patient's initial workup was consistent with CD, and subsequently TSS was performed which failed to correct his hypercortisolemia and clinical symptoms. Histology showed that the removed tissue was normal pituitary with no evidence of adenoma. After referral to our institution, the patient underwent thorough workup including measurement of plasma CRH and ACTH levels, 24-h urinary-free cortisol (UFC), serum cortisol before and after high-dose dexamethasone suppression test (HDDST), CRH stimulation test, inferior petrosal sinus sampling (IPSS), cross-sectional imaging (CT, MRI), and functional imaging with combined PET/CT using 68 Ga-DOTA-TATE (somatostatin analogue) and 18 F-FDG (glucose analogue). 68 Ga-DOTA-TATE PET/CT revealed increased uptake by a thymic nodule (A-axial), whereas 18 F-FDG PET/CT did not show increased glucose metabolism (B-axial). The nodule was also identified on CT (C-axial, D-sagittal) and MRI (E-axial) scans, suggesting a thymic carcinoid. Selective catheterization of a thymic vein was performed showing a step up for ACTH. Total thymectomy was performed and a thymic NET secreting mainly ACTH but also CRH was revealed. . Cells showed focally positive immunostaining for CRH 40Â (D) and diffuse for ACTH 20Â (E) and chromogranin A 20Â (F), characteristic for neuroendocrine neoplasia. Post-thymectomy, the patient's cortisol and ACTH levels remained elevated with persistent CS, probably caused by micrometastatic disease, leading to bilateral adrenalectomy. The patient was discharged with hydrocortisone and fludrocortisone replacement and the recommendation for treatment with octreotide. Ectopic ACTH-secreting tumors, most of which have neuroendocrine origin, account for 8 to 18% of all causes of CS. 1,2 However, ectopic ACTH/CRH co-secreting or CRH-secreting tumors causing CS are very rare with only a few cases reported in the literature. [3] [4] [5] [6] [7] Localization of these tumors is challenging, and the optimal imaging approach is not yet established. 18 F-FDG PET/CT has limited value in detecting NETs especially in well-differentiated tumors with low proliferative activity. [8] [9] [10] [11] However, because the majority of NETs overexpress somatostatin (SST) receptors, they can be effectively targeted and localized using radiolabeled SST analogues. 12 Recent studies have demonstrated the incremental diagnostic information provided by PET/CT using 68 Ga-DOTA-conjugated peptides (SST analogues) in patients with NETs. [13] [14] [15] This was also proven by the presented patient, in whom 68 Ga-DOTA-TATE PET/CT successfully revealed the underlying NET causing CS. This case elucidates the demanding diagnostic workup of patients with CS resulting from ectopic ACTH/CRH co-secreting tumors because the secretion of CRH stimulates the pituitary gland leading towards erroneous diagnosis of CD and unnecessary TSS. Somatostatin receptor imaging using positron emitting radioisotope labeled SST analogues contributes to the early diagnosis and accurate management of these patients.
